Comparative urine protein phenotyping using mass spectrometric immunoassay

被引:45
作者
Kiernan, UA
Tubbs, KA
Nedelkov, D
Niederkofler, EE
McConnell, E
Nelson, RW
机构
[1] Intrins Bioprobes Inc, Tempe, AZ 85281 USA
[2] Arizona State Univ, Tempe, AZ 85287 USA
关键词
proteomics; protein variations; MALDI-TOF; urine; biomarker discovery;
D O I
10.1021/pr025574c
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Reported here, human urine samples were analyzed for beta-2-microglobulin (beta2m), transthyretin (TTR), cystatin C, urine protein 1 (UP1), retinol binding protein (RBP), albumin, transferrin, and human neutrophil defensin peptides (HNP) using mass spectrometric immunoassay (MSIA). MSIA is a unique analytical technique, which allows for the generation of distinct protein profiles of specific target proteins from each subject, which may be subsequently used in comparative protein expression profiling between all subjects. Comparative profiling allows for the rapid identification of variations within individual protein expression profiles. Although the majority of analyses performed in this study revealed homology between study participants, roughly one-quarter showed variation in the protein profiles. Some of these observed variants included a point mutation in TTR, absence of wild-type RBP, monomeric forms UP1, a novel beta2m glycated end product and altered HNP ratios. MSIA has been previously used in the analysis of blood proteins, but this study shows how MSIA easily transitions to the analysis of urine samples. This study displays how qualitative urine protein differentiation is readily achievable with MSIA and is useful in identifying proteomic differences between subjects that might be otherwise overlooked with other analytical techniques due to complexity of the resulting data or insufficient sensitivity.
引用
收藏
页码:191 / 197
页数:7
相关论文
共 61 条
[1]   Iron metabolism [J].
Aisen, P ;
Wessling-Resnick, M ;
Leibold, EA .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (02) :200-206
[2]  
Befus AD, 1999, J IMMUNOL, V163, P947
[3]   Transthyretin amyloidosis [J].
Benson, MD ;
Uemichi, T .
AMYLOID-INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION, 1996, 3 (01) :44-56
[4]  
BERNARD AM, 1994, KIDNEY INT, pS34
[5]  
Broeckaert F, 2000, ANN NY ACAD SCI, V923, P68
[6]   A two-receptor pathway for catabolism of Clara cell secretory protein in the kidney [J].
Burmeister, R ;
Boe, IM ;
Nykjaer, A ;
Jacobsen, C ;
Moestrup, SK ;
Verroust, P ;
Christensen, EI ;
Lund, J ;
Willnow, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :13295-13301
[7]   Tabulation of transthyretin (TTR) variants as of 1/1/2000 [J].
Connors, LH ;
Richardson, AM ;
Théberge, R ;
Costello, CE .
AMYLOID-INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION, 2000, 7 (01) :54-69
[8]   Review: TTR amyloidosis - Structural features leading to protein aggregation and their implications on therapeutic strategies [J].
Damas, AM ;
Saraiva, MJ .
JOURNAL OF STRUCTURAL BIOLOGY, 2000, 130 (2-3) :290-299
[9]  
Dierynck I, 1996, Mult Scler, V1, P385
[10]  
FOGHANDERSEN N, 1993, CLIN CHEM, V39, P48